Trade Agreement: Agreement on Internal Trade (AIT)
Tendering Procedures: Generally only one firm has been invited to bid
Non-Competitive Procurement Strategy: Exclusive Rights
Comprehensive Land Claim Agreement: No
Vendor Name and Address:
GlaxoSmithKline Inc.
7333 Mississauga Road North
Mississauga Ontario
Canada
L5N6L4
Nature of Requirements:
Definition of requirement
This requirement is to provide Hepatitis ?A? & ?B? vaccines (recombinant) in the quantities estimated for use by various Federal, Provincial and Territorial (FPT) Government Department Designated Users under the FPT Group Purchasing Program.
Each consignee will be obligated to purchase only 75% of their maximum estimated quantities.
Item descriptions are as follow:
Item 1: Hepatitis A & B combined vaccine, adult, single dose 1.0ml pre-filled syringue.
Item 2: Hepatitis A and B combined Vaccine, Pediatric Single dose 0.5 ml pre-filled syringe.
Period of proposed contract
Contract period to be from April 1, 2016 to March 31, 2017, with an option to extend the contract period for two additional one-year periods from April 1, 2017 to March 31, 2018 and from April 1, 2018 to March 31, 2019.
Maximum Estimated Quantities
Item 1: 9,774 doses
Item 2: 909 doses
Delivery
Will be on an as-and-when requested basis.
Trade Agreement
The provisions of the WTO-AGP,NAFTA, Canada-Chile Free Trade Agreement (CCFTA) and Canada-Columbia Free Trade Agreement (CCOFTA) and Canada- Peru Free Trade Agreement (CPFTA) are not applicable for reasons connected with the protection of human life and health (see NAFTA article 1018 para. 2 (a) and (b); WTO-AGP article XXIII (2); CCFTA article Kbis-16 para. 2 (b); CCOFTA article 2201 para 3 (a); and CPFTA article 1402 para. 2 (b) ), and because of the absence of regulatory harmonization between Canada and the other signatory countries to the WTO, NAFTA, CCOPTA; CCFTA and CPFTA. This requirement is subject to the Agreement on Internal Trade (AIT).
Canada and PWGSC as Agent
This requirement is for the Federal/Provincial/Territorial (F/P/T) Group Purchasing Program for Drugs andVaccines. Canada is acting as a purchasing agent for Provincial and/or Territorial Governments.
Limited Tendering Reason
It is intended to negotiate directly with GlaxoSmithKline Inc., as they are the only known source of supply licensed by Health Canada’s Biologics and Genetic Therapies Directorate (BGTD) to supply in Canada (licensed under the registered trademark Twinrix®).
Delivery Date: 07/12/2015
You are hereby notified that the government intends to negotiate with one firm only as identified above. Should you have any questions concerning this requirement, contact the contracting officer identified above.
An Advance Contract Award Notice (ACAN) allows departments and agencies to post a notice, for no less than fifteen (15) calendar days, indicating to the supplier community that it intends to award a good, service or construction contract to a pre-identified contractor. If no other supplier submits, on or before the closing date, a Statement of Capabilities that meets the requirements set out in the ACAN, the contracting authority may then proceed with the award. However, should a Statement of Capabilities be found to meet the requirements set out in the ACAN, then the contracting authority will proceed to a full tendering process.
Suppliers who consider themselves fully qualified and available to provide the services/goods described herein, may submit a statement of capabilities in writing to the contact person identified in this Notice on or before the closing date of this Notice. The statement of capabilities must clearly demonstrate how the supplier meets the advertised requirements.
The PWGSC file number, the contracting officer's name and the closing date of the ACAN must appear on the outside of the envelope in block letters or, in the case of a facsimile transmission, on the covering page.
The Crown retains the right to negotiate with suppliers on any procurement.
Documents may be submitted in either official language of Canada.
